Ftse Mib
34.825,01
0,00%
DAX
18.768,96
0,33%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
71.155,92
-0,41%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Allarity Therapeutics Inc (ALLR) Allarity Therapeutics Inc (ALLR) Notizie

ALLR

Allarity Therapeutics (ALLR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALLR
DataOraFonteTitoloSimboloCompagnia
20/05/202414:00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementNASDAQ:ALLRAllarity Therapeutics Inc
17/05/202422:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
15/05/202415:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
14/05/202422:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
14/05/202422:01GlobeNewswire Inc.Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesNASDAQ:ALLRAllarity Therapeutics Inc
08/05/202422:05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:ALLRAllarity Therapeutics Inc
07/05/202415:30GlobeNewswire Inc.Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockNASDAQ:ALLRAllarity Therapeutics Inc
06/05/202414:00GlobeNewswire Inc.Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1NASDAQ:ALLRAllarity Therapeutics Inc
02/05/202414:00GlobeNewswire Inc.Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
29/04/202413:00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:ALLRAllarity Therapeutics Inc
17/04/202415:10GlobeNewswire Inc.Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
04/04/202415:15GlobeNewswire Inc.Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitNASDAQ:ALLRAllarity Therapeutics Inc
27/03/202413:30GlobeNewswire Inc.Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
25/03/202412:30GlobeNewswire Inc.Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
08/03/202413:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALLRAllarity Therapeutics Inc
08/03/202413:15GlobeNewswire Inc.Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ALLRAllarity Therapeutics Inc
08/03/202403:45Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALLRAllarity Therapeutics Inc
28/02/202412:00GlobeNewswire Inc.Allarity Therapeutics to Present at Biomarkers 2024NASDAQ:ALLRAllarity Therapeutics Inc
23/02/202422:09Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:ALLRAllarity Therapeutics Inc
02/02/202423:03Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ALLRAllarity Therapeutics Inc
26/01/202423:07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALLRAllarity Therapeutics Inc
15/12/202323:00Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
12/12/202312:00GlobeNewswire Inc.Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive AdvisorNASDAQ:ALLRAllarity Therapeutics Inc
05/12/202313:30GlobeNewswire Inc.Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion DiagnosticNASDAQ:ALLRAllarity Therapeutics Inc
30/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLRAllarity Therapeutics Inc
02/11/202322:00Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
31/10/202314:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
23/10/202323:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALLRAllarity Therapeutics Inc
17/10/202323:00Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
02/10/202313:00GlobeNewswire Inc.Allarity Therapeutics to Present at Biomarkers Europe 2023NASDAQ:ALLRAllarity Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALLR

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network